Blood Based Biomarkers

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders

Ulf Andreasson\textsuperscript{a,b}, Kaj Blennow\textsuperscript{a,b}, Henrik Zetterberg\textsuperscript{a,b,c,*}

\textsuperscript{a}Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
\textsuperscript{b}Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
\textsuperscript{c}Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK

Abstract

Most research on fluid biomarkers for central nervous system (CNS) disorders has so far been performed using cerebrospinal fluid (CSF) as the biomarker source. CSF has the advantage of being closer to the brain than serum or plasma with a relative enrichment of CNS-specific proteins that are present at very low concentrations in the blood and thus difficult to reliably quantify using standard immunochemical technologies. Recent technical breakthroughs in the field of ultrasensitive assays have started to change this. Here, we review the most established ultrasensitive quantitative technologies that are currently available to general biomarker laboratories and discuss their use in research on biomarkers for CNS disorders.

© 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Blood; Serum; Plasma; Biomarkers; Ultrasensitive; Central nervous system; Alzheimer’s disease

1. Introduction

The goal of biomarker research is to provide objective tools that can be used for example in the clinical diagnostic work-up, as inclusion criteria in clinical trials to enrich for patients with a certain type of pathology and to monitor treatment effects. In the search for biomarkers, it is assumed that the chance of finding good candidates is associated with the proximity to the origin of the disease. In diseases of the central nervous system (CNS), this would suggest that biopsies of the brain or spinal cord would be the ideal specimen to investigate. By its nature, however, this is almost without exception not possible due to the invasiveness of the procedure. Instead, analysis of cerebrospinal fluid (CSF) has been regarded a mirror of the metabolism or pathophysiological changes in the CNS. However, a lumbar puncture is needed to obtain CSF, and this technique is sometimes considered as an invasive procedure and might also give adverse events in the form of post-lumbar puncture headache. Therefore, a Holy Grail of biomarkers for CNS-related diseases would be to measure them in blood, which is more easily accessible.

A proteomic approach using mass spectrometry (MS) is often used in the search for biomarkers, and for small molecules such as amino acids and lipids, MS is also used in clinical routine settings \textsuperscript{[1]}. The advantage of the method is that it directly measures the molecule of interest but on the downside are low throughput and an inability to measure intact larger proteins compared to immunoassays. As the name implies, immunoassays use antibodies to quantify a substance in a sample. A common technique is the sandwich enzyme-linked immunosorbent assay (ELISA) in which most often the analyte is captured between two antibodies in a sandwich-like complex and one of the antibodies carry a signal generator, that is, an enzyme which converts a substrate into a detectable form (colored, fluorescent, or luminescent products) which in combination with a calibrator curve allows for quantification of the analyte of interest. ELISA is a theme with many variations.
such as in the choice of signal generator where the enzyme can be exchanged with for example a fluorophore or a DNA-based system. In a recently described technology, ELISA has been combined with MS-based quantification of the enzymatic products. The technology is called enzyme-linked immuno mass spectrometric assay and may provide increased analytical sensitivity, as compared to regular ELISA, by reducing the background [2]. Immunochemical assays may also be multiplexed in different ELISA-like formats. Such biomarker panels are frequently examined in the current biomarker literature with focus on CNS disorders [3,4]. A downside with multiplexing, however, is that it may be hard to optimize the analytical conditions for several antigen-antibody interactions, especially if their concentrations or biochemical characteristics substantially differ, as compared to optimizing assays that focus on the accurate measurement of a single analyte.

There are several issues, both biological and technical, with the search for CNS-related biomarkers in blood. First, a biomarker that has its origin in the CNS has to cross the blood-brain barrier to be detected in the periphery and if the concentration is low in CSF then it will be even lower in the blood due to the blood:CSF volume ratio causing a substantial dilution. Second, if the biomarker is not specific for the CNS but also produced in the periphery, then the contribution from CNS will potentially drown in the high biological background caused by non-CNS sources (a good tool to assess the risk for this is the publicly available web-based Human Protein Atlas, http://www.proteinatlas.org/, which presents protein expression in 44 different human tissues of close to 20,000 proteins [5]). Third, the huge amount of other proteins in blood (e.g., albumin, immunoglobulins) introduces analytical challenges due to possible interference. Fourth, heterophilic antibodies may be present in blood at high concentrations that may give interference in sandwich immunoassays. Fifth, the analyte of interest may undergo proteolytic degradation by various proteases in plasma.

The technical issues are mainly a question of sensitivity and antibody specificity. Ideally, the enzyme reaction that is the final step in an ELISA should be able to increase the sensitivity by simply extending the reaction time. However, the substrates used are inherently unstable and therefore produce signal even in the absence of enzyme. This leads to a technical background signal that can mask the signal caused by the sandwich complex making quantification difficult at low concentrations. The ability of the sandwich complex to correctly represent the concentration of the biomarker in a sample strongly depends on the quality of the antibodies used. If the antibodies cross-react with other substances then a signal can be measured even in the absence of the biomarker toward which the assay was developed. As the blood is much denser in protein content than is CSF the risk for this is higher in the former.

The biological issues are refractory but the technical ones can be addressed. The production of antibodies is sometimes described as science, art, and magic, and by its nature, some luck is needed to produce high-quality monoclonal antibodies. For the problem with background, however, there are solutions and this is what the ultrasensitive technologies have found different ways of solving.

In this overview article, we focus on describing and discussing currently available ultrasensitive technologies that may be useful for measuring CNS-specific or enriched proteins at low concentrations in the bloodstream.

2. Platforms

Most of the different methods described below build on the sandwich principle for antibody-based quantification discussed above and differ primarily in the method for detection. A brief description of each method is given, and further details can be found in the cited publications. In general, the technologies used are proprietary with the platforms available from only one company. Examples where the platforms have been used in the field of CNS disorders are also given.

2.1. Single-molecule array

Single-molecule array (Simoa) is a digital ELISA that has been invented and commercialized by Quanterix (www.quanterix.com) [6]. After the formation of the sandwich complex on magnetic microbeads, these are transferred, in substrate solution, to an array of 300,000 micro wells. These wells can accommodate only one bead each and, after the addition of a fluorogenic substrate for the enzyme with which the detection antibody is labeled, an oil film is then applied to seal the wells confining the reaction volume to 50 fL. This small volume allows for a readable signal to be detected even if only one sandwich complex is present on the bead. As reporters, the enzyme β-galactosidase and the substrate resorufin-β-D-galactopyranoside are used and the wells having a fluorescent signal are counted as are all the wells containing a bead. The ratio between these counts provides the output average enzyme per bead (AEB) number. When the AEB is low (<0.1), Poisson statistics shows that either a bead has only one or none sandwich complex on its surface, hence the name digital ELISA. When the AEB signal gets higher, increasing the probability of more than one complex per bead, there is a transition to the utilization of also the light intensity which allows for a usable AEB even at signals >0.1. The algorithm for the transition is implemented in the software that comes with the fully automated Simoa instrument to which samples and calibrators can be fed either using a 96-well microtiter plate or vials.

2.2. Single-molecule counting

In the single-molecule counting (SMC) platform, the sandwich complexes, originating either from beads or plates, are broken up and only the fluorescently labeled (Alexa Fluor) detection antibody is drawn into a capillary tube and counted one by one as they pass a laser beam that excites the fluorophore. A digital event is counted if the fluorescence reaches above the threshold of the background. At higher concentrations, it is difficult to separate all events and a switch is made to use the total sum of all emitted photons as readout for the
signal, allowing for a high dynamic range. The SMC technology is proprietary to Singulex (www.singulex.com).

2.3. Proximity extension assay

The polymerase chain reaction (PCR) revolutionized the field of molecular biology by allowing for a single copy of double-stranded DNA to be amplified many orders of magnitude. This amplifying property of PCR can also be used as signal generator in immunochemical assays. The first pilot assay of relevance to CNS diseases exploiting this approach was the so-called bio-barcode assay for Aβ oligomers or amyloid-β-derived diffusible ligands (ADDLs) [7], in which ADDLs were captured in a sandwich between antibody-coated magnetic particles and antibody-coated nanoparticles modified with double-stranded DNA molecules that could then be isolated, released, and amplified to generate a signal. Using this approach, a marked increase in the assay signal for ADDLs was found in autopsy AD CSF [7], but the results have been hard to replicate, and there have been no follow-up publications using this method.

In proximity extension assay (PEA), partly overlapping complementary DNA strands are attached to the different antibodies allowing the strands to hybridize if they are in close proximity [8,9]. After addition of DNA polymerase and deoxynucleotides, a double-stranded PCR template is formed which can be converted to a signal using quantitative real-time PCR. The company Olink (www.olink.com) has a fee-for-service option using PEA, but it is possible to use the technology elsewhere.

2.4. MagQu

The magnetic susceptibility is a physical property that the company MagQu (www.magqu.com) has built their technology around. Magnetic nanoparticles are coated with an antibody, and on binding of the analyte, the oscillation of the particles in an alternating magnetic field is decreased in a concentration-dependent manner, an effect named immunomagnetic reduction (IMR) [10]. Unlike the other assay principles described above, only one antibody is needed for a signal to be generated.

2.5. Utilization of ultrasensitive technologies in the CNS blood biomarker field

In Alzheimer’s disease (AD), the two neuropathological hallmarks are extracellular plaques and intracellular tangles consisting of the amyloid β (Aβ) peptide and hyperphosphorylated tau protein (p-tau), respectively [11]. Together with total tau (T-tau), these are now firmly established CSF biomarkers for AD [12] and a part of the research diagnostic criteria for the disease [13]. For Aβ, the plasma concentration can be measured without the need of ultrasensitive methods but have been found not to correlate with the CSF concentrations, probably due to high extracerebral contributions of Aβ to plasma, and consequently, plasma Aβ does not seem to work as a biomarker for AD [12,14]. However, both Aβ and T-tau in serum, measured using Simoa, are elevated in a time-dependent manner following resuscitation after cardiac arrest, and T-tau also seems to predict neurological outcome [15,16], which is in line with the observation that hypoxia in the brain seems to be a risk factor for AD [17]. T-tau was also found to be mildly increased in plasma in AD compared with both subjects with mild cognitive impairment and healthy controls [18]. In this study, there was a substantial overlap between the groups, making the authors to conclude that plasma T-tau is not useful in a clinical setting. However, a better separation between AD and controls was achieved, when plasma T-tau was assayed using IMR [19]. More studies are needed to better understand the usefulness of plasma T-tau in relation to AD.

Traumatic brain injury (TBI) is caused by external physical force, and apart from accidents, it is also a common consequence of some sports, for example, boxing, ice hockey, and American football. Even at repeated minor head trauma, exemplified by Olympic boxers, T-tau in plasma is elevated compared to controls indicative of axonal injury [20]. The same is true for ice hockey players that had a concussion during play [21] and for military personnel who sustained TBI during deployment [22]. In contrast to tau, neurofilament light (NFL), which is a marker of damage on the large caliber myelinated axons, shows a good correlation between CSF and blood when using a commercial assay for CSF and the same antibody pair and calibrator on the Simoa platform for blood (plasma or serum) [23,24]. NFL is elevated in CSF in boxers after bout where it seems to normalize given enough time of rest from match and training [25] and in American football players, the serum concentration rises over the course of a season in the players who were starters, defined as athletes known to go out with the first or second team, first or second on the depth roster, and take a majority of the repetitions, whereas no increase was observed in the nonstarters [26]. Plasma NFL seems to be a biomarker with multiple utility because it is increased also in subjects with progressive supranuclear palsy [27] and in HIV-associated dementia [24].

The PEA has been used in the search for risk markers for ischemic stroke, where 85 analytes were analyzed in plasma in a targeted proteomic approach [28]. A strength of this study was that it contained two large independent cohorts, which mitigates the risk of false discoveries due to multiple testing. Three proteins (N-terminal pro-B-type natriuretic peptide, adrenomedullin, and eosinophil cationic protein) were found to be related to ischemic stroke in both cohorts [28].

Although the focus of the present overview is on blood markers, it is worth mentioning that ultrasensitive methods are also useful in CSF whenever the concentration of the analyte of interest is too low to be quantified using conventional methods. For example, using SMC, visinin-like protein-1 in CSF has been shown to be increased in AD [29], associated with clinical disease progression [30] and predictive of brain atrophy rates [31]. Also using SMC, Aβ oligomers in CSF were, compared to controls, increased in mild cognitive impairment subjects but not in AD [32],
and for the first time, it was possible to measure the mutant form of huntingtin which causes Huntington’s disease [33].

2.6. Summary

There are presently several different methods that allow for quantification of proteins and peptides in the subfemtomolar range, which allows for the investigation of hypotheses that were previously not possible to test due to the relatively low analytical sensitivity of conventional methods. Although the ultrasensitive methods have not yet revolutionized the CNS blood biomarker field, the future looks promising and more new biomarkers can be expected as the awareness and availability of the platforms will increase. Compared to CSF, blood is further from the origin of the affected organ and also much denser in protein content which makes method development a challenge with regard to specificity and matrix effects, not to mention the risk of interference by heterophilic antibodies.

Acknowledgments

Work in the authors’ laboratories is supported by Swedish State Support for Clinical Research, the Swedish Research Council, the European Research Council, the Torsten Söderberg Foundation and the Knut and Alice Wallenberg Foundation.

References

[1] Brinkmalm A, Portelius E, Ohrfelt A, Brinkmalm G, Andreasson U, Gobom J, et al. Explorative and targeted neuroproteomics in Alzheimer’s disease. Biochim Biophys Acta 2015;1854:769–78.
[2] Florentinus-Mefailoski A, Safi F, Marshall JG. Enzyme linked immunomuno mass spectrometric assay (ELIMA). J Proteomics 2014; 96:343–52.
[3] Berlyand Y, Weintraub D, Xie SX, Mellis IA, Doshi J, Rick J, et al. An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia. PLoS One 2016;11:e0147319.
[4] Chen A, Oakley AE, Monteiro M, Tuomela K, Allan LM, Mukaetovladinska EB, et al. Multiplex analyte assays to characterize different dementias: brain inflammatory cytokines in poststroke and other dementias. Neurobiol Aging 2016;38:56–67.
[5] Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science 2015;347:1260419.
[6] Rissin DM, Kan CW, Campbell TG, Hodges SC, Fournier DR, Song L, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010;28:595–9.
[7] Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc Natl Acad Sci U S A 2005;102:2273–6.
[8] Fredriksson S, Gullberg M, Jarvis J, Olsson C, Petras K, Gustafsdotir SM, et al. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol 2002;20:473–7.
[9] Lundberg M, Thorsen SB, Assarsson E, Villablanca A, Tran B, Gee N, et al. Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material. Mol Cell Proteomics 2011;10:M110 004978.
[10] Chieh JJ, Yang SY, Jian ZF, Wang WC, Honga HE, Yang HC, et al. Hyper-high-sensitivity wash-free magnetoreduction assay on biomolecules using high-T-c superconducting quantum interference devices. J Appl Phys 2008;103.
[11] Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet 2006;368:387–403.
[12] Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol 2016;15:673–84.
[13] Dutois B, Feldman HH, Jacova C, Hampel H, Molinuevo JLR, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13:614–29.
[14] Hansson O, Zetterberg H, Vannemelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:357–67.
[15] Zetterberg H, Mortberg E, Song LA, Chang L, Provuncher GK, Patel PP, et al. Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid beta Levels in Humans. PLoS One 2011;6:e28263.
[16] Randall J, Mortberg E, Provuncher GK, Fournier DR, Duffy DC, Rubertsson S, et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation 2013;84:351–6.
[17] Peers C, Pearson HA, Boyle JP, Hypoxia and Alzheimer’s disease. Essays Biochem 2007;43:153–64.
[18] Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, et al. Plasma tau levels in Alzheimer’s disease. Alzheimers Res Ther 2013;5:9.
[19] Chiu MJ, Yang SY, Hong HE, Yang CC, Chen TF, Chieh JJ, et al. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chem Neurosci 2015;4:1530–6.

RESEARCH IN CONTEXT

1. Systematic review: We searched PubMed for English language articles on ultrasensitive measurement technologies for biomarker research on central nervous system (CNS) disorders using the keywords “biomarker” and “ultrasensitive” or “digital” or “high-sensitivity” or “sensitive”, alone or together with other keywords including: “Alzheimer’s”, “traumatic brain injury”, “neurodegenerative disease”, “CNS”, “plasma”, “serum”, “blood”, “CSF”, and several other keywords relevant to every section. We largely selected publications from the past 5 years but did not exclude important older publications. Selection criteria also included a judgment on the novelty of studies and their relevance for clinical biomarker research for CNS disorders.

2. Interpretation: Our findings suggest that currently available ultrasensitive technologies of relevance to clinical biomarker research on CNS disorders produce promising pilot results. All methods rely on antibody-based detection and quantification, but the specific method for quantification differs between the methods.

3. Future directions: The data so far are promising, and the field is expected to grow substantially during the next few years.
[20] Neselius S, Zetterberg H, Blennow K, Randall J, Wilson D, Marcusson J, et al. Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Inj 2013;27:425–33.
[21] Shahim P, Tegner Y, Wilson DH, Randall J, Skillback T, Pazooki D, et al. Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol 2014;71:684–92.
[22] Olivera A, Lejbman N, Jeromin A, French LM, Kim HS, Cashion A, et al. Peripheral Total Tau in Military Personnel Who Sustain Traumatic Brain Injuries During Deployment. JAMA Neurol 2015;72:1109–16.
[23] Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016; http://dx.doi.org/10.1515/cclm-2015-1195 [in press].
[24] Gisslen M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine 2016;3:135–40.
[25] Neselius S, Brishy H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One 2012;7:e33606.
[26] Oliver JM, Jones MT, Kirk KM, Gable DA, Repshas JT, Johnson TA, et al. Serum Neurofilament Light in American Football Athletes over the Course of a Season. J Neurotrauma 2016; http://dx.doi.org/10.1089/neu.2015.4295 [in press].
[27] Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 2016;3:216–25.
[28] Lind L, Siegbahn A, Lindahl B, Stenemo M, Sundstrom J, Arnlöv J. Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip. Stroke 2015;46:3340–7.
[29] Tarawneh R, D’Angelo G, Macy E, Xiong CJ, Carter D, Cairns NJ, et al. Visinin-like Protein-1: Diagnostic and Prognostic Biomarker in Alzheimer Disease. Ann Neurol 2011;70:274–85.
[30] Kester M, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimers Res Ther 2015;7:59.
[31] Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, et al. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. JAMA Neurol 2015;72:656–65.
[32] Yang T, O’Malley TT, Kannert D, Jerecic J, Zieske LR, Zetterberg H, et al. A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. Alzheimers Res Ther 2015;7:14.
[33] Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J Clin Invest 2015;125:1979–86.